WASHINGTON, D.C. — Cure Coalition welcomes the Treasury Department’s proposal to recognize biotechnology as a national security priority and restrict certain U.S. investments that could strengthen the capabilities of foreign adversaries. By adding biotechnology to the Outbound Investment Security Program, Treasury is acknowledging that biomedical leadership is inseparable from America’s national security, economic resilience, and public health.
As more drug research and development move through China, the United States risks repeating the dependence already seen in pharmaceutical supply chains. That vulnerability is not only an economic concern. It can leave American patients and families with less control over where medicines are developed, whether research meets rigorous U.S. standards, and whether critical treatments remain available during a crisis. Cure Coalition has consistently called for stronger domestic research infrastructure, biomedical manufacturing, and supply-chain transparency to reduce these risks.
But restrictions alone will not restore American leadership. The United States must also rebuild at home by sustaining strong investment in the National Institutes of Health, expanding domestic research and biomanufacturing capacity, and preserving the proven, evidence-based methods that have made American biomedicine the global benchmark. NIH remains the world’s largest public funder of biomedical research and supports research capacity, a skilled workforce, rigorous science, and the translation of discoveries into therapies.
“Treasury’s proposal is an important step, but America cannot secure its biomedical future by playing defense alone,” said Cara Kingan, Executive Director of Cure Coalition. “We must invest in the scientists, facilities, and proven safety standards that allow cures to be discovered and developed here at home. American families deserve medicines they can trust and a research system they can depend on.”
Cure Coalition supports a targeted, carefully implemented approach that protects national security without weakening responsible innovation. Congress and the administration should pair safeguards on risky outbound investment with a durable national commitment to U.S.-led biomedical research. America should not finance the erosion of its own scientific advantage; it should build the next generation of cures here.
About Cure Coalition
Cure Coalition advocates for responsible, evidence-based biomedical research that keeps our families safe and keeps trusted U.S. research approaches as the standard. As mothers, healthcare professionals, and concerned citizens, we’re committed to advancing treatments and cures through medicines Americans can count on. Learn more at curecoalition.org.